Scientists Transplanted Pituitary Organoids Into Macaque
Lab-grown tissue successfully restored hormone production in a primate model, offering a potential path away from daily medication.
Updated on Oct. 14, 2026 in Diabetes
Live Poll
Would you trust lab-grown organoid tissue to replace your need for daily hormone medications?
Researchers have successfully transplanted 1,440 lab-grown human pituitary organoids into a 15-year-old macaque. The procedure allowed the primate to produce its own ACTH, leading it to stop cortisol replacement medication just six days later.
Why it matters
The study aims to create a reliable source of hormone-producing tissue to treat hypopituitarism, which currently forces patients to rely on lifelong hormone pills. By growing these organoids from human embryonic stem cells, scientists hope to provide a functional, long-term alternative to daily pharmacological therapy.
Researchers transplanted 1,440 organoids into a macaque, raising ACTH levels from a 1.5 picograms per milliliter baseline to 6.33 picograms per milliliter. Hypopituitarism affects approximately 45 out of every 100,000 people.
The players
Nagoya University
This institution is a leading Japanese research university that hosted the primary research team involved in developing the pituitary organoids.
Shiga University of Medical Science
This academic medical center served as the specific site where the monkey transplant procedure was successfully conducted.
The details
The team at Nagoya University and the Shiga University of Medical Science derived the organoids from human embryonic stem cells containing hypothalamus tissue and ACTH-making cells. After placing the organoids into the macaque's back tissue and administering immune-suppressing drugs, researchers confirmed that ACTH-making cells remained viable three months post-transplant despite signs of immune rejection.
Timeline
Six days post-transplant the macaque stopped receiving cortisol pills.
Six weeks post-transplant data collection ended due to the monkey's health.
Three months post-transplant researchers identified living ACTH cells in the macaque.
Six months post-transplant transplanted mice showed measurable blood ACTH levels.
The Big Picture
This study advances the field of stem cell-derived pituitary organoid research by demonstrating functional hormone production in a primate model. It marks a significant departure from traditional hormone replacement therapies by shifting the focus toward biological tissue replacement.
For individuals managing hypopituitarism, this development suggests a potential future where daily hormone replacement therapy could be replaced by biological implants. However, clinical-grade scaling and long-term immune suppression safety trials are required before human treatment is possible.
The takeaway
This successful transplant highlights the growing potential of stem cell technology to restore natural hormonal functions in complex biological systems. Ongoing research now focuses on scaling production and refining immune compatibility to ensure these treatments can eventually reach human patients.
Further reading
Learn more about the latest innovations in hormonal health and disease management at Diabetes.
Source note: This article includes information reported by Earth.
Live Poll
Would you trust lab-grown organoid tissue to replace your need for daily hormone medications?
